Patent application number | Description | Published |
20080249068 | Method of Extending the Dose Range of Vitamin D Compounds - Inhibitors of bone calcium resorption are administered, and calcium intake in the subject's diet is restricted, to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating diseases such as metabolic bone diseases, hyperparathyroidism, cancer, psoriasis, and autoimmune diseases without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-κB ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-κB gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1α,25-dihydroxyvitamin D | 10-09-2008 |
20080261925 | COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 10-23-2008 |
20080300223 | (20R)-2a-Methyl-19,26,27-Trinor-Vitamin D Analogs - This invention discloses (20R)-2α-methyl-19,26,27-trinor-vitamin D analogs, and specifically (20R)-2α-methyl-19,26,27-trinor-1α,25-dihydroxyvitamin D | 12-04-2008 |
20090004133 | Methods and compositions for phosphate binding - The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form. | 01-01-2009 |
20090170820 | 2-Methylene-(20S,25R)-19,26-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D | 07-02-2009 |
20090170821 | 2-Methylene-(20S,25S)-19,26-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1α,25-dihydroxyvitamin D | 07-02-2009 |
20090170822 | 2-Methylene-20-Methyl-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D | 07-02-2009 |
20090186950 | 13,13-Dimethyl-des-C,D Analogs of 1Alpha,25-Dihydroxy-19-Nor-Vitamin D3 Compounds and Topical Composition Dosage Forms and Methods of Treating Skin Conditions Thereof - 13,13-Dimethyl-des-C,D analogs of 1α,25-dihydroxy-19-nor-vitamin D | 07-23-2009 |
20090215706 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHOD OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH - Compounds of the formula: | 08-27-2009 |
20090281340 | 1ALPHA-HYDROXY-2-(3'-HYDROXYPROPYLIDENE)-19-NOR-VITAMIN D COMPOUNDS AND METHODS OF MAKING AND TREATMENT THEREOF - Disclosed are 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds, pharmaceutical compositions, and methods of making and treatment thereof. The compounds are generally directed to biologically active 2-alkylidene-19-nor-vitamin D compounds and analogs thereof characterized by the presence of a 3′-hydroxypropylidene moiety at C-2 and the presence of an abbreviated alkyl side-chain free of any hydroxyl moiety. | 11-12-2009 |
20100009940 | 2-Methylene-(20E)-20(22)-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100009941 | 2-Methylene-20(21)-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100009942 | 2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D | 01-14-2010 |
20100009943 | 2-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vit- amin D Analogs - This invention discloses 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-1α,24(R)-dihydroxyvitamin D | 01-14-2010 |
20100009944 | 19-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases. | 01-14-2010 |
20100009945 | 19-NOR-VITAMIN D ANALOGS WITH 3,2-DIHYDROFURAN RING - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases. | 01-14-2010 |
20100009946 | 2-Methylene-19,26-Dinor-(20R,22E,25R)-Vitamin D Analogs - This invention discloses 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20R,22E,25R)-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100009947 | 2-Methylene-19,26-Dinor-(20S,22E,25R)-Vitamin D Analogs - This invention discloses 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20S,22E,25R)-1α,25-dihydroxyvitamin D | 01-14-2010 |
20100029777 | 4-[(E)-2-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPTHALENYL)-1-PROPENYL- ]BENZOIC ACID ANALOGS AND METHOD OF MANUFACTURE AND USE THEREOF - Analogs of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid and methods of manufacture and use thereof, such as for use in cancer prevention and treatment. | 02-04-2010 |
20110003892 | ALL-TRANS RETINOID ESTERS AS ACTIVE PHARMACEUTICAL INGREDIENTS, ORAL AND TOPICAL DOSAGE FORM COMPOSITIONS THEREOF, AND METHODS OF TREATING SKIN CONDITIONS THEREOF - Active pharmaceutical ingredients being retinoic acid ester compounds including all- trans-retinoic acid tent-butyl ester, all-trans-retinoic acid iso-butyl ester, all-trans-retinoic acid iso-propyl ester, all-trans-retinoic acid sec-butyl ester, and, all-trans-retinoic acid 1-adamantyl ester, oral and topical dosage form compositions thereof, and methods of treating various skin conditions thereof. | 01-06-2011 |
20110082121 | 1-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D | 04-07-2011 |
20110082122 | 19-Nor-Vitamin D Analogs With 1,2- or 3,2-Cyclopentene Ring - 19-nor-vitamin D analogs having an additional cyclopentene ring connecting carbon 1 and carbon 2, or connecting carbon 3 and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro activities, making them therapeutic agents for the treatment or prophylaxis of some types of cancers, particularly leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. | 04-07-2011 |
20110082123 | 6-Methylvitamin D3 Analogs and Their Uses - This invention discloses 6-methylvitamin D | 04-07-2011 |
20110086824 | (20S,22E)-2-Methylene-19-Nor-22-Ene-1Alpha,25-Dihydroxyvitamin D3 - This invention discloses (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D | 04-14-2011 |
20110105444 | ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION - An oral dosage form comprising a single dose of 25-hydroxy-vitamin D | 05-05-2011 |
20110195941 | Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 08-11-2011 |
20110212906 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHODS OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH - Compounds of the formula: | 09-01-2011 |
20110237556 | (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 09-29-2011 |
20110237557 | DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 09-29-2011 |
20110294764 | 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 12-01-2011 |
20120157418 | 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D | 06-21-2012 |
20120165300 | DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 06-28-2012 |
20120283227 | (20S)-24-(p-Toluenesulfonyloxy)-25,26,27-Trinorvitamin D3 Analogs and Their Uses - This invention discloses (20S)-24(p-toluenesulfonyloxy)-25,26,27-trinorvitamin D | 11-08-2012 |
20120283228 | 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses - This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D | 11-08-2012 |
20120309719 | (22E)-2-METHYLENE-26,27-CYCLO-22-DEHYDRO-1ALPHA-HYDROXY-19-NORVITAMIN D3 DERIVATIVES - Cyclopropane-containing vitamin D analogs of formulas I and IV are provided. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions. | 12-06-2012 |
20120322775 | 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D | 12-20-2012 |
20130005686 | 2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1α-hydroxyvitamin D | 01-03-2013 |
20130018021 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses - This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D | 01-17-2013 |
20130053356 | 2-METHYLENE-19,23,24-TRINOR-1ALPHA-HYDROXYVITAMIN D3 - Compounds of Formula I are provided where R | 02-28-2013 |
20130178449 | 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydroxyvitamin D | 07-11-2013 |
20130331459 | A-Ring Modified 19-Nor-Vitamin D Analogs and Their Uses - Disclosed are 19-nor-vitamin D compounds, and specifically seco-A-2,19-dinor-1,25-dihydroxyvitamin D | 12-12-2013 |
20140005152 | Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism | 01-02-2014 |
20140011778 | 2-METHYLENE-19,23,24-TRINOR-1ALPHA-HYDROXYVITAMIN D3 - Compounds of Formula I are provided where R | 01-09-2014 |
20140018332 | METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D | 01-16-2014 |
20140100203 | ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION - An oral dosage form comprising a single dose of 25-hydroxy-vitamin D | 04-10-2014 |
20140187522 | Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism - Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D | 07-03-2014 |
20140206655 | (22E)-2-METHYLENE-22-DEHYDRO-1ALPHA,24,25-TRIHYDROXY-19-NOR-VITAMIN D3 ANALOGS - Disclosed are (22E)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitamin D | 07-24-2014 |